Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
1 other identifier
observational
60
1 country
1
Brief Summary
This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 12, 2023
CompletedFirst Posted
Study publicly available on registry
June 22, 2023
CompletedStudy Start
First participant enrolled
December 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 25, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 25, 2028
December 26, 2025
December 1, 2025
1.5 years
June 12, 2023
December 19, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
major pathological response
3 months after radiation therapy
Secondary Outcomes (2)
Progression-free Survival
2 years after radiation therapy
Overall Survival
2 years after radiation therapy
Study Arms (1)
Observation Group
Interventions
Intensity modulated radiation therapy (IMRT) combined with chemotherapy
Eligibility Criteria
Patients with newly histologically confirmed stage IVa nasopharyngeal carcinoma
You may qualify if:
- Patients with newly histologically confirmed nasopharyngeal carcinoma
- No evidence of distant metastasis (M0)
- Written informed consent
You may not qualify if:
- Treatment with palliative intent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Jiangsu Cancer Hospital
Nanjing, China
Biospecimen
Whole blood is obtained from patients when recruited, completing 10, 20, 32 fractions of radiation therapy, 3 months after radiation therapy and disease progression. Tumor tissue specimens are obtained from patients when recruited and disease progression.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
June 12, 2023
First Posted
June 22, 2023
Study Start
December 25, 2025
Primary Completion (Estimated)
June 25, 2027
Study Completion (Estimated)
December 25, 2028
Last Updated
December 26, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL